Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Soleno Therapeutics Inc SLNO

Healthcare Biotechnology
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3... see more

Recent & Breaking News (NDAQ:SLNO)

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a

GlobeNewswire June 2, 2021

Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021

GlobeNewswire May 21, 2021

Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit

GlobeNewswire May 20, 2021

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

GlobeNewswire May 5, 2021

Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall

GlobeNewswire April 14, 2021

Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference

GlobeNewswire March 9, 2021

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the Firm

ACCESSWIRE IA March 9, 2021

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

GlobeNewswire March 8, 2021

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

GlobeNewswire March 3, 2021

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

GlobeNewswire February 23, 2021

Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

GlobeNewswire February 5, 2021

Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome

GlobeNewswire January 28, 2021

Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

GlobeNewswire January 4, 2021

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

GlobeNewswire December 11, 2020

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results

GlobeNewswire November 10, 2020

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

GlobeNewswire November 3, 2020

Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting

GlobeNewswire October 29, 2020

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

GlobeNewswire September 30, 2020

Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GlobeNewswire September 15, 2020

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results

GlobeNewswire August 10, 2020